Cogent Biosciences signs commercial supply deal with Hovione for bezuclastinibSep 2PartnershipbezuclastinibCogent Biosciences, Inc.
Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates aheadAug 10Quarterly updatebezuclastinibCogent Biosciences, Inc.
Cogent Biosciences files $400 million stock offering under existing at-the-market programAug 10FinancingbezuclastinibCogent Biosciences, Inc.
Sign in